MA38156A1 - Utilisation du pidotimod pour traiter la dermatite atopique - Google Patents
Utilisation du pidotimod pour traiter la dermatite atopiqueInfo
- Publication number
- MA38156A1 MA38156A1 MA38156A MA38156A MA38156A1 MA 38156 A1 MA38156 A1 MA 38156A1 MA 38156 A MA38156 A MA 38156A MA 38156 A MA38156 A MA 38156A MA 38156 A1 MA38156 A1 MA 38156A1
- Authority
- MA
- Morocco
- Prior art keywords
- pidotimod
- atopic dermatitis
- treat atopic
- acceptable salt
- present
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title abstract 3
- 229960001163 pidotimod Drugs 0.000 title abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention porte sur l'utilisation du pidotimod, ou d'un sel physiologiquement acceptable, pour traiter la dermatite atopique. Dans le cadre du traitement de la présente invention, le pidotimod ou son sel physiologiquement acceptable, est administré de préférence par voie topique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076086 WO2014094839A1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter la dermatite atopique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38156A1 true MA38156A1 (fr) | 2016-08-31 |
| MA38156B1 MA38156B1 (fr) | 2017-03-31 |
Family
ID=47520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38156A MA38156B1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter la dermatite atopique |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150352081A1 (fr) |
| EP (1) | EP2934520B1 (fr) |
| JP (1) | JP6058156B2 (fr) |
| KR (1) | KR20150095772A (fr) |
| CN (1) | CN104797254B (fr) |
| AU (1) | AU2012396941A1 (fr) |
| BR (1) | BR112015011394A2 (fr) |
| CA (1) | CA2889388A1 (fr) |
| CY (1) | CY1118633T1 (fr) |
| DK (1) | DK2934520T3 (fr) |
| EA (1) | EA201591184A1 (fr) |
| EC (1) | ECSP15025570A (fr) |
| ES (1) | ES2615748T3 (fr) |
| HR (1) | HRP20161667T1 (fr) |
| HU (1) | HUE030408T2 (fr) |
| IL (1) | IL239292A0 (fr) |
| LT (1) | LT2934520T (fr) |
| MA (1) | MA38156B1 (fr) |
| ME (1) | ME02559B (fr) |
| MX (1) | MX2015008129A (fr) |
| PH (1) | PH12015501211A1 (fr) |
| PL (1) | PL2934520T3 (fr) |
| PT (1) | PT2934520T (fr) |
| RS (1) | RS55424B1 (fr) |
| SG (1) | SG11201503281QA (fr) |
| SI (1) | SI2934520T1 (fr) |
| SM (2) | SMT201700071T1 (fr) |
| TN (1) | TN2015000159A1 (fr) |
| UY (1) | UY35197A (fr) |
| WO (1) | WO2014094839A1 (fr) |
| ZA (1) | ZA201502983B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (fr) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod à utiliser dans le traitement de maladies associées à une inflammation |
| EP3754806A1 (fr) | 2019-06-19 | 2020-12-23 | UTC Fire & Security EMEA BVBA | Dispositif d'alimentation électrique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| AU2002363939A1 (en) * | 2001-11-20 | 2003-06-10 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| EP1688161A1 (fr) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
-
2012
- 2012-12-19 HU HUE12812220A patent/HUE030408T2/en unknown
- 2012-12-19 SM SM20170071T patent/SMT201700071T1/it unknown
- 2012-12-19 BR BR112015011394A patent/BR112015011394A2/pt not_active IP Right Cessation
- 2012-12-19 WO PCT/EP2012/076086 patent/WO2014094839A1/fr not_active Ceased
- 2012-12-19 LT LTEP12812220.7T patent/LT2934520T/lt unknown
- 2012-12-19 SG SG11201503281QA patent/SG11201503281QA/en unknown
- 2012-12-19 HR HRP20161667TT patent/HRP20161667T1/hr unknown
- 2012-12-19 EP EP12812220.7A patent/EP2934520B1/fr active Active
- 2012-12-19 MA MA38156A patent/MA38156B1/fr unknown
- 2012-12-19 KR KR1020157018214A patent/KR20150095772A/ko not_active Withdrawn
- 2012-12-19 ES ES12812220.7T patent/ES2615748T3/es active Active
- 2012-12-19 CN CN201280077173.2A patent/CN104797254B/zh active Active
- 2012-12-19 SI SI201230863A patent/SI2934520T1/sl unknown
- 2012-12-19 PL PL12812220T patent/PL2934520T3/pl unknown
- 2012-12-19 US US14/652,472 patent/US20150352081A1/en not_active Abandoned
- 2012-12-19 PT PT128122207T patent/PT2934520T/pt unknown
- 2012-12-19 RS RS20161045A patent/RS55424B1/sr unknown
- 2012-12-19 MX MX2015008129A patent/MX2015008129A/es unknown
- 2012-12-19 JP JP2015548220A patent/JP6058156B2/ja not_active Expired - Fee Related
- 2012-12-19 EA EA201591184A patent/EA201591184A1/ru unknown
- 2012-12-19 CA CA2889388A patent/CA2889388A1/fr not_active Abandoned
- 2012-12-19 ME MEP-2016-275A patent/ME02559B/fr unknown
- 2012-12-19 AU AU2012396941A patent/AU2012396941A1/en not_active Abandoned
- 2012-12-19 DK DK12812220.7T patent/DK2934520T3/en active
-
2013
- 2013-12-17 UY UY0001035197A patent/UY35197A/es not_active Application Discontinuation
-
2015
- 2015-04-24 TN TNP2015000159A patent/TN2015000159A1/fr unknown
- 2015-04-30 ZA ZA2015/02983A patent/ZA201502983B/en unknown
- 2015-05-29 PH PH12015501211A patent/PH12015501211A1/en unknown
- 2015-06-08 IL IL239292A patent/IL239292A0/en unknown
- 2015-06-16 EC ECIEPI201525570A patent/ECSP15025570A/es unknown
-
2017
- 2017-01-30 SM SM201700071T patent/SMT201700071B/it unknown
- 2017-02-14 CY CY20171100199T patent/CY1118633T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2683382A4 (fr) | Régimes posologiques pour le traitement de la maladie de fabry | |
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| EP2827847A4 (fr) | Complexes contenant du strontium administré par voie topique pour le traitement de la douleur, du prurit et de l'inflammation | |
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| MY192055A (en) | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| EP2614838A4 (fr) | Agent pour le traitement de l'oeil sec caractérisé par la combinaison d'un agoniste de récepteur p2y² et d'acide hyaluronique ou son sel, procédé pour traiter l'oeil sec, utilisation de l'agoniste de récepteur p2y² et d'acide hyaluronique ou son sel | |
| EP2844279A4 (fr) | Schéma posologique pour le traitement de la maladie de pompe | |
| EP2654745A4 (fr) | Composition pour le traitement d'états pathologiques de la peau | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MY165160A (en) | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS | |
| EP2544699A4 (fr) | Nouvelle méthode d'administration et d'utilisation d'isothiocyanates pour la prophylaxie et/ou le traitement du cancer de la vessie | |
| EP2702992A4 (fr) | Utilisation de mélatonine pour le traitement et/ou la prévention de la mucosite | |
| CA3010788A1 (fr) | Procedes d'administration de vasopresseurs | |
| EP2790712A4 (fr) | Sous-population de monocytes humains pour le traitement d'une lésion du système nerveux central | |
| MA38156A1 (fr) | Utilisation du pidotimod pour traiter la dermatite atopique | |
| EP2540299A4 (fr) | Gouttes ophtalmiques pour le traitement d'une infection ophtalmique contenant de la lévofloxacine, son sel ou son solvate, méthode de traitement d'une infection ophtalmique, lévofloxacine, son sel ou son solvate, et leur utilisation | |
| MA38155A1 (fr) | Utilisation du pidotimod pour traiter le psoriasis | |
| EP2870971A4 (fr) | Médicament pour la prévention/le traitement d'une maladie oculaire | |
| EP2928460A4 (fr) | Procédés pour la prévention et le traitement d'affections cutanées inflammatoires | |
| EP2884988A4 (fr) | Inhibiteurs de rac1 pour le traitement de la maladie glomérulaire d'alport | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| EP3448529A4 (fr) | Pansement hydrocolloïde médicamenteux pour traitement de l'acné | |
| MX2025002392A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| FR2953832B1 (fr) | Derives de nouveaux peroxydes, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique pour le traitement ou la prevention de l'acne |